pn 401 has been researched along with fluorouracil in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Bertino, J; Kelsen, DP; Martin, D; O'Neil, J; Saltz, L; Schwartz, G; Sung, MT; von Borstel, R | 1 |
| Campbell, E; Davidson, K; Diab, SG; Drengler, RL; Eckhardt, SG; Garner, AM; Hammond, LA; Hidalgo, M; Louie, A; O'Neil, JD; Rodriguez, G; Rowinsky, EK; Villalona-Calero, MA; von Borstel, R; Von Hoff, DD; Weiss, G | 1 |
| Al Safarjalani, ON; Ashour, OM; el Kouni, MH; Naguib, FN; Panzica, RP | 1 |
| Saif, MW; von Borstel, R | 1 |
| Kemeny, NE; Leonard, GD | 1 |
| Abbruzzese, JL; Cobb, PW; Doroshow, JH; Issell, BF; Macdonald, JS; McCoy, S; Patel, T; Yost, KJ | 1 |
| Traynor, K | 1 |
| Diasio, RB; Saif, MW | 1 |
| Bai, G; Beaver, JA; Charlab, R; Chen, XH; Cheng, J; Dinin, J; Dorff, SE; Ibrahim, A; Ison, G; Jin, R; Kim, G; Liu, Q; Marathe, A; McGuinn, WD; McKee, AE; Palmby, TR; Pazdur, R; Pierce, W; Sridhara, R; Stephens, O; Tang, S; Wang, Y; Ysern, X | 1 |
| Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW | 1 |
| Wilkinson, E | 1 |
| Galuski, K; Gil, B; Nugent, FW; Vaudo, CE; Zarwan, C | 1 |
| Geller, RJ; Morgan, BW; Santos, C | 1 |
| Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D | 1 |
| Bamat, MK; Garcia, RAG; Saydoff, JA; von Borstel, RW | 1 |
| Brutcher, E; Christensen, D; Hennessey Smith, M; Koutlas, JB; Sellers, JB; Thompson, J; Timmons, T | 1 |
| Robert, J | 1 |
| Leung, M; Rogers, JE; Shureiqi, I | 1 |
3 review(s) available for pn 401 and fluorouracil
| Article | Year |
|---|---|
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Topics: Acetates; Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; Fluorouracil; Humans; Neoplasms; Prescription Drug Overuse; Research Design; Treatment Outcome; United States; United States Food and Drug Administration; Uridine | 2016 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Pyrrolidines; Quinazolines; Thiophenes; Thymine; Trifluridine; Uracil; Uridine | 2018 |
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Topics: Acetates; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Patient Safety; Risk Assessment; Severity of Illness Index; Survival Analysis; Uridine | 2018 |
3 trial(s) available for pn 401 and fluorouracil
| Article | Year |
|---|---|
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Topics: Acetates; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Uridine | 1997 |
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Topics: Acetates; Adult; Antimetabolites, Antineoplastic; Cytoprotection; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Neutropenia; Prodrugs; Statistics, Nonparametric; Uridine | 2000 |
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
Topics: Acetates; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Uridine | 2006 |
13 other study(ies) available for pn 401 and fluorouracil
| Article | Year |
|---|---|
Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.
Topics: Acetates; Animals; Antimetabolites, Antineoplastic; Barbiturates; Drug Interactions; Enzyme Inhibitors; Female; Fluorouracil; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Prodrugs; Tumor Cells, Cultured; Uridine; Uridine Phosphorylase | 2000 |
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Topics: Acetates; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Survival Rate; Tumor Burden; Uridine; Xenograft Model Antitumor Assays | 2006 |
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunologic Factors; Leucovorin; Liver Neoplasms; Male; Methotrexate; Middle Aged; Phosphonoacetic Acid; Remission Induction; Uridine; Vitamin B Complex | 2006 |
FDA approves therapy to treat overdose of fluorouracil, capecitabine.
Topics: Acetates; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemistry, Pharmaceutical; Drug Approval; Drug Overdose; Fluorouracil; Humans; United States; United States Food and Drug Administration; Uridine | 2016 |
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans; Male; Pancreatic Neoplasms; Severity of Illness Index; Time Factors; Uridine | 2016 |
In brief: uridine triacetate (Vistogard) for fluorouracil overdose.
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Drug Overdose; Fluorouracil; Humans; Treatment Outcome; Uridine | 2016 |
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Topics: Acetates; Antimetabolites, Antineoplastic; Capecitabine; Drug Overdose; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Uridine | 2017 |
An antidote to fluorouracil and capecitabine toxicity.
Topics: Acetates; Antidotes; Antineoplastic Agents; Capecitabine; Drug Costs; Drug Overdose; Fluorouracil; Humans; Treatment Outcome; Uridine | 2016 |
Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Anus Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fatigue; Fluorouracil; Follow-Up Studies; Humans; Male; Mucositis; Mutation; Neutrophils; Time Factors; Uridine | 2016 |
The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
Topics: Acetates; Antimetabolites, Antineoplastic; Anus Neoplasms; Depression; Drug Overdose; Emergency Medicine; Fluorouracil; HIV Infections; Humans; Male; Middle Aged; Toxoplasmosis, Cerebral; Treatment Outcome; Uridine | 2017 |
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Topics: Acetates; Animals; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Drug Overdose; Female; Fluorouracil; Mice; Survival Analysis; Uridine | 2018 |
[5-FU: At last!]
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Neoplasms; Practice Guidelines as Topic; Pyrimidines; Uracil; Uridine | 2019 |
Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.
Topics: Acetates; Fluorouracil; Humans; Neoplasms; Uridine | 2021 |